Clinical data supporting CBPs are usually derived from prospective antifungal trials primarily involving adults. 12, 13 Antifungal PK are not the same between premature infants and adults. 14 Moreover, clinical course and outcome of IC differs in premature infants who are at higher risk of meningoencephalitis and NDI. [15] [16] [17] Therefore, correlation between antifungal MIC and clinical outcome may differ in premature infants compared with older children or adults. Studies assessing Candida susceptibility and clinical outcomes are limited by small sample size, or by combining infants and adults in the same cohort. [18] [19] [20] We therefore performed an analysis of data collected in the Neonatal Research Network (NRN) Candida study to describe the antifungal MIC distribution for Candida in ELBW infants and to evaluate the association between antifungal resistance and death or NDI.
MATERIALS AND METHODS

Study Population
This study included infants enrolled in the prospective NICHD-NRN study, "Neonatal Candidiasis: Epidemiology, Risk Factors, and Clinical Judgment." 15 The objective of this former study was to identify risk factors for neonatal candidiasis. The study cohort included 1515 ELBW infants evaluated for possible sepsis between 3 and 120 days of life at 19 NRN sites from March 2004 through July 2007. In the current study, we included infants from this cohort diagnosed with IC. The institutional review board at each center approved participation in the registry and the follow-up studies. Written informed consent for participation in the study was obtained from parents or legal guardians.
Definitions
We defined IC as having ≥ 1 positive cultures for Candida from blood, urine (obtained by catheterization or suprapubic aspiration), cerebrospinal fluid, or other sterile body source. Choice of antifungal therapy was at the discretion of the attending neonatologist and included amphotericin B deoxycholate, lipid complex amphotericin, micafungin and fluconazole. Species were independently identified by matrix-assisted laser desorption ionizationtime of flight mass spectrometry, and antifungal susceptibility testing was performed by broth microdilution according to the Clinical and Laboratory Standards Institute (CLSI) M27-A3 reference standard at the University of Texas Health Science Center at San Antonio Fungus Testing Laboratory. [21] [22] [23] An infant was categorized in the resistant group if he had ≥ 1 Candida isolate from a sterile body source that was resistant to ≥ 1 of the 3 antifungals tested. A Candida isolate was classified as resistant according to the CBPs in the CLSI M27-S4 document (Table 1) . 24, 25 Current MIC determination methods for amphotericin B generate a restricted range of MICs, precluding reliable discrimination between susceptible and resistant Candida isolates. We therefore considered an isolate likely resistant to amphotericin B if MIC was ≥ 2 mg/L as suggested by the CLSI. 23 There is no established fluconazole CBP established for C. guillermondii, and no fluconazole and micafungin CBPs established for C. lusitaniae. The epidemiologic cutoff values were therefore used to identify strains with decreased susceptibility (Table 1) . [25] [26] [27] In addition to resistance status based on CBPs, we categorized fungal isolates as having a low or a high MIC (Table 1) . The high MIC cutoff value was defined as the MIC required to inhibit 90% of a given Candida species (MIC 90 ). For Candida species with ≤ 10 isolates, MIC 90 could not be estimated, and the high MIC cutoff was defined as the epidemiologic cutoff value published in the literature. If an infant had multiple positive Candida cultures, the isolate with the highest MIC for a given antifungal, was used in the analysis.
The primary outcome of our analysis was the composite of death or NDI at 18-22 months of corrected age. 28 NDI evaluation included the Bayley Scales of Infant Development (BSID) II (for infants born before 2006) or III ( Table 2 ). Secondary outcomes included length of hospital stay and therapy failure. Therapy failure was defined for infants treated with an antifungal drug within 3 days of first positive Candida culture, as any of: (1) death within 14 days of therapy initiation; (2) endorgan involvement; and (3) persistent Candida infection defined by ≥ 1 positive blood or cerebral spinal fluid cultures > 14 days after therapy initiation. End-organ involvement was defined as the following: (1) at least 1 cerebral spinal fluid positive culture for Candida; (2) ophthalmoscopy findings consistent with endophthalmitis; (3) echocardiography findings consistent with endocarditis or large sessile mass on the wall of the myocardium; and (4) echogenic findings consistent with abscesses in the liver, spleen or kidney.
Statistical Analysis
We described infants' baseline characteristics using median and range for continuous variables, and counts and proportions for categorical variables. The proportion of infants infected with ≥ 1 resistant Candida was also described at the infant level for each antifungal. Candida species, distribution of MIC and proportion of resistant isolates to each antifungal were described at the isolate level. MIC 50 and MIC 90 , defined as the MIC required to inhibit growth of 50% and 90% of the isolates for 1 given species, were described for each Candida species with > 10 isolates available for analysis. We quantified variation in categorical outcomes (death or NDI, and therapy failure) related to Candida MIC (low and high; Table Supplemental Digital Content 1, http://links.lww. com/INF/C953) and antifungal resistance, using logistic regression and adjusting for gestational age (GA) and being born before or after 2006 (cohort 1 or 2). In 2006, the Network Follow-Up study changed the psychometric instrument used to evaluate neurocognitive functioning from the BSID II to the BSID III. Among survivors, length of hospital stay was compared between infants with high MIC to any antifungal and those with only low MIC using the Wilcoxon rank-sum test. All statistical tests were 2-sided, with significance defined as P < 0.05. Antifungals Species www.pidj.com | 925
RESULTS
Among the 1515 infants enrolled, 137 (9%) developed IC, and 110/137 (80%) had MIC results (321 total Candida isolates from sterile sites; Fig. 1 ). Thirteen isolates were excluded from this analysis either because species identification was not successful (n = 4), or Candida isolates could not be linked to a subject from the main analysis (n = 9). Hence, the resulting number of Candida isolates used in this analysis was 308 from a total of 110 infants. Median (range) GA was 25 (23-29) weeks, and median postnatal age at first positive culture was 19 (4-84) days (Table Supplemental  Digital Table 3 ). Four infants had 2 different Candida sp., leading to a total of 114 infant-Candida sp. Among those 114 infants-Candida sp, distribution of MIC suggested that fluconazole and amphotericin B MIC distributions were similar for C. albicans and C. parapsilosis (Fig. 2) . However, micafungin MIC values were higher for C. parapsilosis relative to C. albicans (Fig. 2) All Candida isolates were susceptible to amphotericin B deoxycholate and micafungin (Table 3) . Three Candida isolates (2 C. albicans, and 1 C. glabrata), each from a different infant, were resistant to fluconazole (MIC of 64 mg/L; Table 3 ). Those 3 infants were male, with GA ranging from 24 to 26 weeks and were 5-81 days at first positive culture. None of them had received prior antifungal prophylaxis, and they were from 3 different sites.
Of the 110 infants, 46 (42%) infants had a high MIC to any antifungal. More specifically, 25 (23%), 0 (0), and 43 (39%) infants had a Candida isolate with a high MIC to fluconazole, amphotericin B deoxycholate and micafungin, respectively. There was no significant difference in the number of infants with antifungal prophylaxis (nystatin or fluconazole), among infants with a high MIC to any antifungal (3 [7%] ) versus those with only low MIC (6 [9%]; P > 0.73). Site proportions of Candida isolates with a high MIC to any antifungal were more variable for C. parapsilosis than for C. albicans ( 
Outcomes
Nine infants (8%) were lost to follow-up by 18-22 months. Among the 101 infants with known status, 39 (39%) infants died by 18-22 months (Table 4) . Among 62 infants who survived, 20 (32%) had NDI, and 2 infants did not complete the evaluation. Among infants with complete data, 59 (60%) either died or had NDI by 18-22 months follow-up. Among infants with C. albicans and parapsilosis, which are the most common species, 35 (59%) and 20 (61%) infants experienced death or NDI, respectively. All infants who had a Candida isolate with a fluconazole MIC ≥ 2 mg/L either died or had NDI (Fig. 3) . Among the 3 infants with a Candida isolate resistant to fluconazole, 2 died, while the third had NDI. Too few Candida isolates were resistant when using the CBPs (n = 3) to allow the correlation between outcome and antifungal resistance. There was no significant difference in the rates of death, NDI, or death/NDI among infants with a high MIC to any antifungal versus those with low MIC (Table 4 ). This result still held after limiting the analysis to infants treated with fluconazole (Table 4) . We did not perform a subgroup analysis of clinical outcomes by micafungin MIC in the subgroup of infants who were actually treated with micafungin because of their limited number (n = 8). Similarly, no subgroup analysis for amphotericin B was performed because no Candida isolates had a high MIC to that antifungal.
Among 60 infants who survived to follow-up at 18-22 months, median (range) length of hospital stay was 118 days (69-268), and median postmenstrual age at discharge was 41 weeks www.pidj.com | 927
(37-65 weeks). There was no significant difference in length of stay between infants with high and low MIC, 114 days (76-268) versus 122 days (69-203), respectively, P = 0.38, nor in postmenstrual age at discharge, 41 (37-65) weeks versus 42 (37-53) weeks, respectively, P = 0.35. Nine (26%) of 34 infants administered fluconazole experienced therapeutic failure. However, there was no significant difference in the rate of therapy failure between those with high versus low fluconazole MIC (Table 4) .
DISCUSSION
This study evaluated antifungal susceptibility to the 3 most common antifungals used in the neonatal intensive care unit in a cohort of ELBW infants infected with Candida and determined the correlation between MIC and clinical outcome. Antifungal resistance was uncommon in this large cohort of ELBW infants with IC, and higher MIC did not predict clinical outcome.
C. albicans and C. parapsilosis were the 2 most frequent species causing invasive infection (> 90%) in our cohort, consistent with previous reports. 2, 4, 6, 7, 18, 29 Although C. glabrata was the third most frequent species, it represented only 3% of all species. This finding is consistent with previous publications in which it is significantly less frequent than in adults. 12, 29 MIC distribution for amphotericin B was clustered around 1 mg/L for all species. Our results are similar to amphotericin MIC results against Candida isolates previously described in 3 cohorts of neonates in which few (0-8%) Candida sp from normally sterile sites had an MIC ≥ 2 mg/L. 18, 30, 31 In a previous cohort of 322 premature infants (< 1500 g birth weight), all infecting and colonizing Candida isolates had an MIC < 2 mg/L. 32 The amphotericin B MIC 90 we observed for C. albicans and C. parapsilosis (1 mg/L for both species) was similar to that previously described in the cohort of 322 premature infants (0.125 and 1 mg/L for infecting and colonizing isolates, respectively). 33 Given that current methods for MIC determination do not reliably discriminate between Candida isolates susceptible and resistant to amphotericin B, the correlation between clinical outcome and amphotericin MIC cannot be detected. 23 Fluconazole resistance was uncommon (3 [3%] infants) in this study. Previously described cohorts of premature infants have reported that no Candida isolates were resistant to fluconazole. 6, 30, 31, [33] [34] [35] This difference may be explained by the change of CBPs in 2012 for C. albicans, C. parapsilosis and C. tropicalis. For these 3 species, the MIC cutoff for fluconazole resistance decreased from 64 to 8 mg/L. 24, 36 Previous reports of fluconazole MIC against Candida species in premature infants were usually interpreted with previous CLSI breakpoints, therefore possibly underestimating fluconazole resistance.
Micafungin susceptibility data against Candida isolates in premature infants are very limited. Reports of micafungin MIC values come from mixed populations, including neonates, children and adults. In a cohort of patients (infants and adults) with C. parapsilosis fungemia (330 isolates), 2.4% of isolates were resistant to micafungin with an MIC 50 and MIC 90 of 1 and 2 mg/L, respectively. 37 In a cohort of 200 children (0-15 years) with Candida fungemia, micafungin resistance occurred in 1% of both C. albicans, and C. parapsilosis. MIC 50/90 were 0.016/0.03 mg/L and 1/2 mg/L against C. albicans, and C. parapsilosis, respectively. 32 These results are similar to what we observed in our cohort of ELBW infants.
Infants with IC suffered high rates of mortality (39%) and NDI (33%). These findings were similar to previous studies of premature infants with IC where mortality of 22-41%, and NDI incidence of 30% have been reported. 8, 29 Invasive infection caused by Candida isolates with high MIC may reduce antifungal efficacy and increase time to clear the pathogen from the infected site. This is all the more significant in infants with meningoencephalitis for whom antifungal penetration into the central nervous system may be insufficient against Candida species with decreased susceptibility. In the present study, the number of resistant Candida isolates was too small to detect a correlation between antifungal resistance and clinical outcome. We also analyzed outcomes by MIC, using high and low cutoff values to define susceptible ranges, but were unable to detect significant differences. Previous studies correlating in vitro susceptibility testing against Candida and clinical outcome have yielded conflicting results. In mixed cohorts including infants and adults (> 90% adults) with C. albicans fungemia, all-cause 30-days mortality was increased when MIC was equal or superior to 4 mg/L. 38 In another cohort including infants and adults with C. glabrata fungemia, elevated MICs were associated with clinical failure. 39 Lastly, consistent with our results, data from a small, single-center study in 38 young infants failed to correlate antifungal MIC to clinical outcome in infants with candidemia. 18 Our study is the first large cohort of infants < 1000 g birth weight with data on resistant Candida isolates, using latest speciesspecific CBPs, and evaluating data on micafungin susceptibility. Limitations of this study include the lack of dosing information, and therefore we could not adjust our analysis for this important covariate. We speculate that fluconazole dosing was lower than doses currently recommended, based on PK studies published after the original NRN study. 40 Another limitation is that our primary analysis focused on the correlation of outcomes and MIC to any antifungal, regardless of the antifungal (single or combined therapy) that was used for definitive treatment. However, a subgroup analysis of those treated with fluconazole did not show a correlation of fluconazole MIC and outcomes. Because there was no infant who had high amphotericin B MIC, and because of the limited number of infants who were treated with micafungin, we could not perform this analysis for those 2 antifungals. Our ability to assess fluconazole therapy failure was limited by the small number of infants with high MIC who experienced this outcome and the lack of data on central line dwell time. Of note, the Bayley score used to assess NDI changed over the study period, and some experts have expressed concern that the Bayley score III (cohort 2; 2006-2007) underestimates disabilities. 41 However, all 3 infants with resistant isolates were in cohort 1 and were assessed with the Bayley score II. Finally, some infants were lost to follow-up. All these limitations may have impaired our ability to assess the effect of MIC on clinical outcome.
CONCLUSIONS
Antifungal resistance was rare among Candida isolates causing IC in ELBW infants. Infection with a Candida sp displaying high MIC was not associated with higher risk of death or NDI in this cohort of ELBW infants.
